Prevail Therapeutics Inc.

Prevail Therapeutics Inc. (PRVL) priced its initial public offering on Jun 20, 2019 at $17.00 per share, within its $16.00–$18.00 range, raising $125M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $578M. Cooley advised the company and Latham & Watkins advised the underwriters.

Prevail Therapeutics Inc. is a gene therapy company developing AAV-based gene therapies for neurodegenerative diseases in genetically defined patient groups. Its lead program, PR001, targets Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease, and other programs address frontotemporal dementia and synucleinopathies.

Status

IPO

Ticker

PRVL

Exchange

Nasdaq Global Market

Priced

Jun 20, 2019

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$125M

Market cap at IPO price

$578M

First filed

May 24, 2019

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.